suPAR na avaliação do prognóstico após permanência na unidade de terapia intensiva: um estudo piloto

suPAR na avaliação do prognóstico após permanência na unidade de terapia intensiva: um estudo piloto

RESUMO Objetivo: Determinar o desempenho da dosagem do receptor ativador de plasminogênio tipo uroquinase solúvel quando da alta da unidade de terapia intensiva para predição da mortalidade após permanência na mesma unidade. Métodos: Durante 24 meses conduziu-se um estudo prospectivo observacional...

Full description

Bibliographic Details
Main Authors:	Joana Silvestre, Luis Coelho, João Gonçalves Pereira, Vitor Mendes, Camila Tapadinhas, Pedro Póvoa
Format:	Article
Language:	English
Published:	Associação de Medicina Intensiva Brasileira 2019-01-01
Series:	Revista Brasileira de Terapia Intensiva
Subjects:	Receptors, urokinase plasminogen activator C-reactive protein Biomarkers Prognosis
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-507X2019005001101&lng=en&tlng=en

Similar Items

suPAR: An Inflammatory Mediator for Kidneys
by: Yashwanth Reddy Sudhini, et al.
Published: (2022-06-01)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
by: Ourania S. Kotsiou, et al.
Published: (2022-10-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients
by: Ria M. Holstein, et al.
Published: (2022-06-01)

The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults
by: Niklas Fabio Wohlwend, et al.
Published: (2023-09-01)

suPAR to Risk-Stratify Patients With Malaria
by: Veselina Stefanova, et al.
Published: (2022-06-01)

suPAR as a prognostic biomarker in sepsis
by: Donadello Katia, et al.
Published: (2012-01-01)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
by: Burcin Özdirik, et al.
Published: (2020-05-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
by: Dženita Ljuca, et al.
Published: (2007-05-01)

suPAR as a marker of infection in acute kidney injury – a prospective observational study
by: Anna Hall, et al.
Published: (2018-08-01)

suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients
by: Jeppe Meyer, et al.
Published: (2018-02-01)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
by: Jan Simon Scharrenberg, et al.
Published: (2019-11-01)

Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients
by: Esben Iversen, et al.
Published: (2020-06-01)

suPAR remains uninfluenced by surgery in septic patients with bloodstream infection
by: Rabensteiner, Jasmin, et al.
Published: (2016-07-01)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
by: Rafał Nikodem Wlazeł, et al.
Published: (2023-05-01)

A study of the interaction between Helicobacter pylori and components of the human fibrinolytic system
by: A. Yarzábal, et al.
Published: (2000-09-01)

Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
by: Abderrahim Oulhaj, et al.
Published: (2021-06-01)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
by: Salim S. Hayek, et al.
Published: (2018-05-01)

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion
by: Synnove Norvoll Magnussen, et al.
Published: (2017-05-01)

Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain
by: Manuel Yepes
Published: (2020-01-01)

Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department
by: Anne Byriel Walls, et al.
Published: (2021-08-01)

Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications
by: Filomena Napolitano, et al.
Published: (2022-05-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
by: Koh, Angela S., et al.
Published: (2018)

Activación y determinación de parámetros cinéticos de la Plasmina Humana y Ovis aries
by: Omaira Cañas, et al.
Published: (2011-01-01)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
by: Shirin Kouhpayeh, et al.
Published: (2017-01-01)

Values of serum PCT, suPAR combined with severity scores for evaluating prognosis of septic shock patients
by: Wang Wenxin, et al.
Published: (2021-10-01)

Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines
by: Paola Pontecorvi, et al.
Published: (2019-12-01)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
by: Torry A. Tucker, et al.
Published: (2021-02-01)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
by: T. Grinenko, et al.
Published: (2019-12-01)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
by: Lampelj Maja, et al.
Published: (2015-12-01)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2018-02-01)

Reduced Expression of Urokinase Plasminogen Activator in Brown Adipose Tissue of Obese Mouse Models
by: Chung-Ze Wu, et al.
Published: (2021-03-01)

Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review
by: Paola Manzo, et al.
Published: (2023-06-01)

Inhibitory effects of wogonin on invasion by human oral cancer cells by decreasing the activity of matrix metalloproteinases and urokinase-plasminogen activator
by: Yung-Chuan Ho, et al.
Published: (2014-06-01)

Specific inhibitors of urokinase plasminogen activator for treatment of cancers; In silico approach
by: Benjamin Talbot, et al.
Published: (2020-05-01)

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge
by: Krzysztof Kowal,, et al.
Published: (2010-04-01)

The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer
by: Hein Vincent Stroomberg, et al.
Published: (2020-10-01)

Immunohistochemical study of the plasminogen activator system in benign epithelial odontogenic lesions
by: Carla Samily de Oliveira Costa, et al.
Published: (2022-05-01)

Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study
by: Salim S. Hayek, et al.
Published: (2017-05-01)

Simulated in vitro hypoxic conditions from psoriatic arthritis cartilage change plasminogen activating system urokinase and serpine functionality. Reversal of antiapoptotic protection suggests common homeostatic buffering
by: Michal Nohawica, et al.
Published: (2022-02-01)

SuPAR-based choice of the management strategy in kidney transplant recipients with infection
by: N. V. Rapetskaya, et al.
Published: (2020-10-01)